Ventures V, Llc Vivo Net Worth

The estimated Net Worth of Ventures V, Llc Vivo is at least $8.97 million dollars as of 5 November 2015. Ventures Vivo owns over 22,693 units of Soleno Therapeutics Inc stock worth over $8,927,401 and over the last 10 years Ventures sold SLNO stock worth over $41,755.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Vivo SLNO stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the Soleno Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Ventures sold 22,693 units of SLNO stock worth $41,755 on 5 November 2015.

The largest trade Ventures's ever made was selling 22,693 units of Soleno Therapeutics Inc stock on 5 November 2015 worth over $41,755. On average, Ventures trades about 4,539 units every 0 days since 2015. As of 5 November 2015 Ventures still owns at least 183,767 units of Soleno Therapeutics Inc stock.

You can see the complete history of Ventures Vivo stock trades at the bottom of the page.

What's Ventures Vivo's mailing address?

Ventures's mailing address filed with the SEC is 505 HAMILTON AVENUE, SUITE 207, , PALO ALTO, CA, 94301.

Insiders trading at Soleno Therapeutics Inc

Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler et Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.

What does Soleno Therapeutics Inc do?

soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.

Complete history of Ventures Vivo stock trades at MEI Pharma Inc et Soleno Therapeutics Inc

Soleno Therapeutics Inc executives and stock owners

Soleno Therapeutics Inc executives and other stock owners filed with the SEC include:

• Anish Bhatnagar,
  President, Chief Executive Officer, Director
• Dr. Anish Bhatnagar,
  Pres, CEO, COO & Director
• Patricia Hirano,
  Vice President - Regulatory Affairs
• Kristen Yen,
  Vice President - Clinical Operations
• James H. MacKaness,
  Chief Financial Officer
• Ernest Mario,
  Independent Chairman of the Board
• William Harris,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Birgitte Volck,
  Independent Director
• Andrew Sinclair,
  Independent Director
• Dr. Neil M. Cowen M.B.A., Ph.D., MBA,
  Sr. VP of Drug Devel.
• Anthony Wondka,
  Sr. VP & GM
• Dawn Carter Bir,
  
• Jack W Schuler,
  
• Larry N Feinberg,
  10% owner
• Opportunity, Llc Vivo Oppor...,
  
• Jonathan Wolter,
  Chief Financial Officer
• Stephen Kirnon,
  Director
• Mahendra Shah,
  Director
• Rajen Dalal,
  Director
• Edgar Engleman,
  Director
• Ventures V, Llc Vivo,
  10% owner
• Steinar J Engelsen,
  Director
• James Walter Glasheen,
  Director
• Stuart J Collinson,
  Director
• Ventures V, Llc Vivo Ventur...,
  
• Raymond W. Urbanski,
  CHIEF DEVELOPMENT OFFICER
• Management Vii Llctechnolog...,
  
• Mangement Llcbioasia Invest...,
  
• Larry Noracle Partners Lp F...,
  
• Llp Abingworth,
  10% owner
• Ventures V, Llc Vivo Ventur...,
  
• Group Inc.Carlyle Holdings ...,
  
• Meredith Manning,
  Chief Commercial Officer
• Michael F. Huang,
  Sr. VP of Clinical Development
• Matthew Pauls,
  
• Group Inc.Carlyle Holdings ...,
  
• Advisors Llcperceptive Life...,
  
• James H Mackaness,
  CHIEF FINANCIAL OFFICER